Navigation Links
AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
Date:2/11/2008

MINNEAPOLIS, Feb. 11 /PRNewswire/ -- AGA Medical Corporation ("AGA") announced today it received European CE Mark approval for the AMPLATZER(R) Duct Occluder II ("ADO II"). AGA also announced the immediate availability and launch of the device in Europe. The ADO II expands the AGA family of occlusion devices designed to occlude or close a patent ductus arteriosus ("PDA"), a type of congenital heart defect that occurs when a blood vessel called the ductus arteriosus fails to close after birth, as it normally should.

"We believe the new ADO II represents a development milestone for AGA Medical and demonstrates the success of our product development programs," said Franck Gougeon, President and CEO of AGA. "It is our first approved occlusion device designed to treat structural heart defects that does not include fabric to assist in rapid occlusion. This expands the type of ducts that can be closed by our family of PDA devices."

The ADO II is a self-expanding nitinol mesh device and is designed to be introduced in a minimally invasive fashion through a catheter. The device has two retention disks positioned on either side of the duct and connected by a waist. The ADO II is designed with a screw mechanism for attachment to the deployment cable that allows the device to be withdrawn and repositioned, if necessary, prior to release from the cable.

The device treats a PDA. The ductus arteriosus is an open channel in every fetus that allows blood to bypass the lungs, which are not used until the baby takes its first breath after birth. Shortly after the baby's first breath, the ductus arteriosus should close permanently. If it does not close, it is known as a PDA. This condition can cause symptoms such as fatigue, difficulty or rapid breathing, failure to grow normally, or chronic respiratory infections such as colds and pneumonia, or endocarditis.

"The ADO II greatly improves treatment options for babies and young children because it can b
'/>"/>

SOURCE AGA Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
2. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
3. BioMS Medical to present at BIO CEO & Investor Conference
4. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
5. Linc Facility Services Acquires Morse Medical
6. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program
9. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
10. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
11. Medical University of South Carolina Opens State-of-the-Art Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer of ... participated in the American Urology Association’s (AUA) surgical ... opinion leaders in urology presented on the latest ... masses while attendees had the opportunity to evaluate ... labs. Attendees at the Los Angeles, CA lab, ...
(Date:11/26/2014)... 25, 2014 The Pittcon marketing department ... conference and exposition mobile app, Pittcon ... in the App Store for iOS and Android devices ... tool before, during and after the event. It acts ... exhibiting companies, technical sessions, Conferee Networking sessions and short ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... 2014 Theravalues Corporation est fier d,annoncer ... européen au salon Hi Europe 2014 (du 2 ... Curcumine la plus biodisponible actuellement sur ... à des ingrédients approuvés par les règlements européens. ... présent dans la racine de curcuma ( Curcuma ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... , , WARSAW, ... ZMH ; SWX: ZMH) today announced the launch of the new ... surgeons and subject matter experts to develop a unique model for ... Surgeon-to-Surgeon programs under one, consolidated service offering, the enhanced Zimmer Institute ...
... EL SEGUNDO, Calif., July 27 NASA has exercised a ... continuing support to the Space Life Sciences Directorate at NASA,s Johnson ... The work will be done by Wyle,s Integrated Science and ... the bioastronautics contract, Wyle,s work supports the International Space Station, space ...
... , SOUTH PLAINFIELD, N.J., July 27 ... Phase 2 clinical trial of PTC299 in adult patients with ... the development of non-malignant brain tumors. PTC299 is a ... selectively block tumor-related vascular endothelial growth factor (VEGF). With ...
Cached Biology Technology:Zimmer Launches New Medical Education and BioSkills Training Program 2Zimmer Launches New Medical Education and BioSkills Training Program 3Zimmer Launches New Medical Education and BioSkills Training Program 4NASA Extends Bioastronautics Contract With Wyle for Total Value of $976 Million 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... burn cleaner, a research report published in the January ... the food industry could take a similar approach toward ... additives would be based on work of Israeli researchers ... wine, fruits, and vegetables) simultaneously with high-fat foods may ...
... a higher prevalence of body abnormalities, such as asymmetric lower ... defect responsible for the abnormality may play a role in ... January 2 issue of JAMA. Certain genetic syndromes ... cancer development in children. Several studies have shown that developmental ...
... that doctors treating life-threatening emergencies such as allergy attacks may ... labelling. Adrenaline is stored in salt water in glass ... The amount of adrenaline contained in the ampoule is ... drug per 1 mL of salt water) and a ratio ...
Cached Biology News:Study examines genetic defects linked to body abnormalities in patients with childhood cancer 2Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 2
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Request Info...
Biology Products: